Profusa, Inc. (NASDAQ:PFSA) Stock Short Interest Declines 51.5%

by · The Markets Daily

Profusa, Inc. (NASDAQ:PFSA – Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 77,845 shares, a drop of 51.5% from the September 30th total of 160,653 shares. Based on an average trading volume of 645,641 shares, the days-to-cover ratio is presently 0.1 days. Currently, 15.1% of the company’s shares are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Wall Street Zen upgraded shares of Profusa to a “sell” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Get Our Latest Analysis on PFSA

Insider Activity at Profusa

In related news, major shareholder Financial Lp Hrt sold 10,602 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total value of $37,743.12. Following the sale, the insider directly owned 18,549 shares in the company, valued at $66,034.44. This represents a 36.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 15.00% of the stock is currently owned by corporate insiders.

Profusa Trading Down 9.2%

Shares of PFSA traded down $0.07 during trading hours on Friday, reaching $0.70. 161,331 shares of the stock traded hands, compared to its average volume of 2,742,092. Profusa has a 52 week low of $0.69 and a 52 week high of $1,962.75. The company has a market cap of $427,061.00, a price-to-earnings ratio of -0.00 and a beta of 0.53. The stock has a fifty day simple moving average of $2.07 and a 200 day simple moving average of $100.73.

Profusa (NASDAQ:PFSA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Profusa Company Profile

(Get Free Report)

Profusa, Inc is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling.

The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.

Profusa’s technology combines a small, injectable hydrogel sensor with optical detection and wireless data transmission.

See Also